Join our daily newsletter At The Bell to receive exclusive market insights
- Nyrada (NYR) says its new brain injury drug candidate NYR-BI02 has shown “excellent oral bioavailability” and will be put to the test in a phase-one clinical study
- The company says NYR-BI02 is the result of modifications made to NYR-BI01, improving the compound’s overall drug-like properties
- Recent exploratory studies undertaken as part of Nyrada’s medicinal chemistry program have revealed excellent oral bioavailability of NYR-BI02, according to the company
- Nyrada says its drug has the potential to be administered orally to patients who suffer a concussion, where intravenous infusion is not preferred
- NYR shares up 5.13 per cent to 20.5 cents
Nyrada (NYR) says its new brain injury drug candidate NYR-BI02 has shown “excellent oral bioavailability” and will be put to the test in a phase-one clinical study later this year.
The company says NYR-BI02 is the result of modifications made to NYR-BI01, improving the compound’s overall drug-like properties.
There is currently no FDA-approved drug to treat secondary brain injury caused by traumatic brain injury (TBI) and stroke.
Recent exploratory pharmacokinetic studies undertaken as part of Nyrada’s medicinal chemistry program revealed excellent oral bioavailability of NYR-BI02, according to the company.
As a result Nyrada says its drug has the potential to be administered orally to patients who suffer a concussion, where intravenous infusion is not preferred.
The convenience of an oral dosage form that can be administered in the field immediately after a concussion injury, without having to wait for hospitalisation, has the potential to significantly improve patient recovery outcomes, the company says.
“The oral bioavailability of NYR-BI02 opens the door for its development as an oral treatment for concussion, which accounts for around 85 per cent of all TBIs,” CEO James Bonnar said.
“Pursuing NYR-BI02’s development as an oral treatment for concussion is an additional program we may consider, given the significant interest in this area and the positive effect it could have on patient outcomes.”
Optimisation of NYR-BI01 has led to the improved candidate NYR-BI02, which has a superior pharmacokinetic profile, meaning it is absorbed, metabolised and cleared in a manner that supports oral dosing, Nyrada explains.
The company anticipates commencing the phase-one first-in-human study for its brain injury program in the second half of CY2022.
The study will be run in Australia and evaluate the safety and tolerability of its preferred brain injury drug candidate NYR-BI02.
NYR shares were up 5.13 per cent to 20.5 cents at 11:06 am AEDT.
-1200x645-380x200.jpg)
